Pharmacokinetics of the thymidine analog 2′-fluoro-5-[14C]-methyl-1-β-D-arabinofuranosyluracil ([14C]FMAU) in rat prostate tumor cells

Nuclear Medicine and Biology

Volumn 27, Issue 4, 2000, Pages 361-368

  Bading, James R ^a,b   Shahinian, Antranik H ^a   Bathija, Pravin ^a   Conn, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cell growth; DNA; Positron emission tomography; Thymidine analog; Tumor

Indexed keywords

2'-FLUORO-5-METHYLARABINOSYLURACIL; ANTIVIRUS AGENT; CLEVUDINE; DNA; DRUG DERIVATIVE; THYMIDINE; URACIL ARABINOSIDE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; MALE; METABOLISM; PROSTATE TUMOR; RAT;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DNA; MALE; PROSTATIC NEOPLASMS; RATS; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0034181442     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(00)00100-1     Document Type: Article

References (33)

1. Bosland M. C. (1999) Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur. Urol. 35, 459-463.
2. Chou T.-C., Kong X.-B., Fanucchi M. P., Cheng Y.-C, Takahashi K., Watanabe K. A. and Fox J. J. (1987) Synthesis and biological effects of 2′-fluoro-5-ethyl-1-β-D-arabinofuranosyluracil. Antimicrob. Agents Chemother. 31, 1355-1358.
3. Christman D., Crawford E. J., Friedkin M. and Wolf A. P. (1972) Detection of DNA synthesis in intact organisms with positron-emitting [methyl [C-11]] thymidine. Proc. Natl. Acad. Sci. 69, 988-992.
4. Cleaver J. E. (1967) Thymidine metabolism and cell kinetics. Front. Biol. 6, 43-100.
5. 11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl. Med. Biol. 22, 783-789.
6. Fanucchi M. P., Leyland-Jones B., Young C. W., Burchenal J. H., Watanabe K. A. and Fox J. J. (1985) Phase I trial of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat. Rep. 69, 55-59.
7. Fuerst J., Fiebiger E., Jungwirth A., Mack D., Talwar P. G., Frick J. and Rovan E. (1997) Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines. The Prostate 32, 77-84.
8. Gautschi J. R., Burkhalter M. and Baumann E. A. (1978) Comparative utilization of bromodeoxyuridine and iododeoxyuridine triphosphates for mammalian DNA replication in vitro. Biochim. Biophys. Acta 518, 31-36.
9. Getzenberg R. H., Light B. W., Lapco P. E., Konety B. R., Nangia A. K., Acierno J. S., Dhir R., Shurin Z., Day R. S., Trump D. L. and Johnson C. S. (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50, 999-1006.
10. Hauschka P. V. (1974) Analysis of nucleotide pools in animal cells. In: Methods in Cell Biology, vol. 7 (Edited by Prescott D. M.), p. 367.
11. Herr H. W., Kleinert E. L., Relyea N. M. and Whitmore W. F. Jr. (1984) Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoro-methylornithine in rat prostate cancer. Cancer 53, 1294-1298.
12. Higashi K., Clavo A. C. and Wahl R. L. (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med. 34, 414-419.
13. Higashi T., Tamaki N., Torizuka T., Nakamoto Y., Sakahara H., Kimura T., Honda T., Inokuma T., Katsushima S., Ohshio G., Imamura M. and Konishi J. (1998) FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J. Nucl. Med. 39, 1727-1735.
14. Kong X.-B., Zhu Q.-Y., Vidal P. M., Watanabe K. A., Polsky B., Armstrong D., Ostrander M. and Lang S. A. Jr. (1992) Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 36, 808-818.
15. Leung K. K. and Visser D. W. (1976) Characteristics of deoxythymidine transport and deoxythymidine kinase in 3T3 cells. Biochem. Med. 16, 127-137.
16. Link J. M., Grierson J. and Krohn K. (1995) Alternatives in the synthesis of 2-[C-l l]-thymidine. J. Labelled Compd. Radiopharm. 37, 610-612.
17. 11C]thymidine PET imaging studies: Validation studies. J. Nucl. Med. 40, 614-624.
18. Martiat P., Ferrant A., Labar D., Cogneau M., Bol A., Michel C., Michaux J. L. and Sokal G. (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. Nucl. Med. 29, 1633-1637.
19. Miyazawa, H., Arai T., Iio M. and Hara T. (1993) PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: Relationship between radioactivity uptake and flow-cytometric parameters. J. Nucl. Med. 34, 1886-1891.
20. Nottebrock H. and Then R. (1977) Thymidine concentrations in serum and urine of different animal species and man. Biochem. Pharmacol. 26, 2175-2179.
21. Peschke P. P., Hahn E. W., Wenz F., Lohr F., Braunschweig F., Wolber G., Zuna I. and Wannenmacher M. (1998) Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia. Radiat. Res. 150, 423-430.
22. Philips F. S., Feinberg A., Chou T.-C., Vidal P. M., Su T.-L., Watanabe K. A. and Fox J. J. (1983) Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine. Cancer Res. 43, 3619-3627.
23. Rubinow S. I. (1975) Introduction to Mathematical Biology. J. Wiley & Sons, New York.
24. Shields A. F., Mankoff D. A., Link J. M., Graham M. M., Eary J. F., Kozawa S. M., Zheng M., Lewellen B., Lewellen T. K., Grierson J. R. and Krohn K. A. (1998) Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med. 39, 1757-1762.
25. Shields A. F., Grierson J. R., Dohmen B. M., Machulla H. J., Stayanoff J. C., Lawhorn-Crews J. M., Obradovich J. F., Muzik O. and Mangner T. J. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 4, 1334-1336.
26. Shields A. F., Grierson J. R., Muzik O., Stayanoff J. C., Lawhorn-Crews H. M, Obradovich J. E. and Mangner T. J. (1999) [F-18]FLT imaging and modeling in dogs. J. Nucl. Med. 40(suppl), 25P.
27. Shields A. F., Dohmen B. M., Grierson J. R., Kuntzsch M., Machulla H.-J. and Bares R. (1999) Imaging with [F-18]FIT and FDG in patients with cancer. J. Nucl. Med. 40(suppl), 61P.
28. Spears C. P., Shani J., Shahinian A. H., Wolf W., Heidelberger C. and Danenberg P. V. (1985) Assay and time course of 5-fluorouracil into RNA of L1210/0 ascites cells in vivo. Mol. Pharmacol. 27, 302-307.
29. Sundoro-Wu B. M., Schmall B., Conti P. S., Dahl J. R., Drumm P. and Jacobsen J. K. (1984) Selective alkylation of pyrimidyl-dianions: Synthesis and purification of C labeled thymidine for tumor visualization using positron emission tomography. Int. J. Appl. Radiat, Isot. 35, 705-708.
30. Tjuvajev J., Muraki A., Ginos J., Berk J., Koutcher J., Ballon D., Beattie B., Finn R. and Blasberg R. (1993) Iododeoxyuridine uptake and retention as a measure of tumor growth. J. Nucl. Med. 34, 1152-1162.
31. Wang J. and Eriksson S. (1996) Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob. Agents Chemother. 40, 1555-1557.
32. Watanabe K. A., Reichman U., Hirota K., Lopez C. and Fox J. J. (1979) Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosylpyrimidine nucleosides. J. Med. Chem. 22, 21-24.
33. Wohlhueter R. M., Marz R., Graff J. C. and Plagemann P. G. W. (1976) The application of rapid kinetic techniques to the transport of thymidine and 3-O-methylglucose into mammalian cells in suspension culture. J. Cell. Physiol. 89, 605-612.